Biotech
Aug. 11, 2011
Michael J. Shuster
Shuster counsels biotechnology and medical device clients, such as Cambridge, Mass.-based Alnylam Pharmaceuticals Inc., on patent strategy.
Alnylam is developing therapies based on ribonucleic acid interference, or RNAi, to treat genetic diseases.
"It's still a technology that is experimental in some regards, but it's a very powerful molecular medicine," Shuster said.
He also advises companies working in persona...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In